Clinical trial Recruiting at 1 site Interventional Ages 10 to 18

TXA in kids undergoing scoliosis surgery

Official title: Efficacy and Safety of Two Intravenous Tranexamic Acid Regimens Versus Placebo in Pediatric Idiopathic Scoliosis Surgery: A Randomized Double-Blind Trial

Run by Poznan University of Medical Sciences · NCT07581457 · Data updated 2026-11-12

This trial tests whether tranexamic acid can reduce blood loss and the need for transfusions in children aged 10–18 having surgery for idiopathic scoliosis.

More Scoliosis trials

Quick facts

Study typeInterventional
Ages10 Years to 18 Years
SexAll
Enrollment90 (estimated)
SponsorPoznan University of Medical Sciences
Academic / other
Locations1 site (Poznan)
StatusRecruiting
StartedMay 6, 2026
Main results expectedMay 31, 2027
Study endsJune 30, 2027
Registry record updatedNovember 5, 2026
Trial IDNCT07581457 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Candidates are aged 10–18 with idiopathic scoliosis requiring posterior spinal fusion and ASA I–II, with parental consent and child assent.

Probably not a fit

Patients with coagulation disorders, history of thromboembolism, seizures, renal impairment, or allergy to tranexamic acid may not benefit and could be excluded.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, double-blind, placebo-controlled study evaluating two intravenous TXA dosing regimens against placebo in children undergoing posterior spinal fusion for idiopathic scoliosis. Participants are randomly assigned to receive either a TXA bolus with continuous infusion, two TXA bolus doses, or saline, with neither patients nor clinicians knowing the assignment. The primary outcome is perioperative blood loss, while secondary outcomes include transfusion requirements, laboratory changes, and safety events such as seizures or thrombosis, followed up to 30 days post-surgery. All procedures follow standardized anesthesia, regional analgesia, and intraoperative neuromonitoring per institutional protocols. The trial aims to clarify optimal TXA use in this pediatric surgical setting.

Why it matters

Potential benefit: If successful, TXA could reduce blood loss and transfusion needs for children undergoing scoliosis surgery.

How similar studies have gone: Previous adult and pediatric studies have shown TXA can reduce bleeding in orthopedic surgeries, but pediatric data in scoliosis surgery are limited and tailored dosing remains under investigation.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 10 to 18 years
* Diagnosis of idiopathic scoliosis requiring surgical correction (posterior spinal fusion)
* American Society of Anesthesiologists (ASA) physical status I-II
* Written informed consent from parents or legal guardians and assent from the child

Exclusion Criteria:

* Congenital or acquired coagulopathy
* History of thromboembolic disease
* History of seizures or epilepsy
* Known hypersensitivity to tranexamic acid
* Renal insufficiency (estimated glomerular filtration rate \< 60 mL/min/1.73 m²)
* Cardiac arrhythmias or cardiovascular disease requiring antiplatelet or anticoagulant therapy

Where it's running

  • Poznan University of Medical Sciences
    Poznan, Poland
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.